Gyre Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Gyre Therapeutics, Inc. (GYRE) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $88.59 million as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-03-13
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $88.59M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $190.38M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $444.20M.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $12.67M; Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed $1.05M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2025-12-31 | $88.59M 10-K · filed 2026-03-13 | |
| 2024-12-31 | $190.38M 10-K · filed 2026-03-13 | |
| 2023-12-31 | $444.20M 10-K · filed 2025-03-17 | |
| 2022-12-31 | $12.67M 10-K · filed 2024-03-27 | $1.05M 10-K · filed 2023-03-30 |
| 2020-12-31 | $1.34M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $1.35M 10-K · filed 2022-03-31 | |
| 2018-12-31 | $2.29M 10-K · filed 2021-03-04 | |
| 2017-12-31 | $6.38M 10-K · filed 2020-02-20 | |
| 2015-12-31 | $16.00K 10-K · filed 2018-03-19 | $11.06K 10-K · filed 2016-03-09 |
| 2014-12-31 | $2.00K 10-K · filed 2015-03-16 | |
| 2013-12-31 | $372.29M 10-K · filed 2014-03-14 | |
| 2012-12-31 | $624.54M 10-K · filed 2013-03-15 | |
| 2011-12-31 | $6.29K 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |